Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.43 |
| ▸ | CTSL | P07711 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450934 | 0.93 | CASP1 (0.51) | CTSKCTSLCTSSCASP1CTSB | |
| SCHEMBL13197149 | 0.93 | CASP1 (0.51) | CTSKCTSLCTSSCASP1CTSB | |
| SCHEMBL950190 | 0.83 | CASP1 (0.52) | CASP1XIAPBIRC3BIRC2 | |
| SCHEMBL950189 | 0.83 | CASP1 (0.52) | CASP1XIAPBIRC3BIRC2 | |
| SCHEMBL12946457 | 0.83 | CASP1 (0.42) | CASP1ALDH1A1XIAPBIRC3BIRC2 | |
| SCHEMBL14370033 | 0.83 | CASP1 (0.52) | CASP1XIAPBIRC3BIRC2 | |
| SCHEMBL12914620 | 0.83 | CASP1 (0.52) | CASP1XIAPBIRC3BIRC2 | |
| SCHEMBL12450522 | 0.82 | CASP1 (0.46) | CASP1XIAPBIRC3BIRC2 | |
| SCHEMBL14370034 | 0.79 | CASP1 (0.53) | CTSKCTSLCTSSCASP1CTSB | |
| SCHEMBL8763113 | 0.78 | XIAP (0.43) | ALDH1A1XIAPBIRC3BIRC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CTSK 114/4885CTSL 105/4885CTSS 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.